| Predicate |
Object |
| contentType |
Journal Article|Research Support, N.I.H., Extramural |
| endingPage |
470 |
| issn |
1539-1612
1539-1604 |
| issueIdentifier |
6 |
| pageRange |
459-470 |
| publicationName |
Pharmaceutical Statistics |
| startingPage |
459 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_916de93fe8f49855f42e16db43537393
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_07bea0375836b42642b357413a763117 |
| isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_9c99d0e8b604930181bd67879dd34f8e |
| bibliographicCitation |
Jiang W, Mahnken JD, He J, Mayo MS. Generalized optimal design for two‐arm, randomized phase II clinical trials with endpoints from the exponential dispersion family. Pharmaceutical Statistics. 2016 Aug 11;15(6):459–70. doi: 10.1002/pst.1769. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54a5ee79d2889ef59c2f546bb3b97cd6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bccf55f92104d7cb36d663b38185567b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_721420d50af7cd3e65f5adba4bbfc3f9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9 |
| date |
2016-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.1002/pst.1769
https://pubmed.ncbi.nlm.nih.gov/27511063 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1539-1604
https://portal.issn.org/resource/ISSN/1539-1612
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33099 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Generalized optimal design for two‐arm, randomized phase II clinical trials with endpoints from the exponential dispersion family |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D016032Q000379
http://id.nlm.nih.gov/mesh/D012107
http://id.nlm.nih.gov/mesh/D017322Q000379 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D018401
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D023381 |